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Abstract: Long-acting bronchodilators have been shown to improve multiple clinical outcomes 
in chronic obstructive pulmonary disease (COPD) including lung function, symptoms, dyspnea, 
quality of life, and exacerbations. Indacaterol is a novel, inhaled, long-acting β2-agonist providing 
24-hour bronchodilation with once-daily dosing. It is currently approved for the maintenance 
treatment of COPD to be administered as 150 or 300 µg once-daily doses as licensed in many 
countries and 75 µg as licensed in the US by means of a single-dose dry powder inhaler. The 
data from clinical development support a favorable safety and tolerability profile within the 
β2-agonist drug class, with no relevant issues identified. Current evidence indicates that inda-
caterol is suitable for use as first-line monotherapy in COPD patients with moderate disease 
(Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II) and beyond that do 
not require an inhaled corticosteroid (ICS) as per GOLD guidelines, or in combination with 
an ICS in severe or very severe patients with repeated exacerbations. Data from trials with the 
novel once-daily β2-agonist, indacaterol, indicate superior bronchodilation and clinical efficacy 
over twice-daily long-acting β2-agonists and at least equipotent bronchodilation as once-daily 
tiotropium. Bronchodilators are central in the symptomatic management of COPD. It is likely 
that once-daily dosing of a bronchodilator would be a significant convenience and probably a 
compliance-enhancing advantage, leading to improved overall clinical outcomes in patients 
with COPD.
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Emerging treatment options in COPD
Chronic obstructive pulmonary disease (COPD) is a progressive obstructive airways 
disease with incomplete improvement in lung function in response to therapy. COPD is 
estimated to affect 10% of the world’s population aged $40 years and its prevalence is 
expected to continue to increase over the next decade or more.1 An accelerated decline 
in forced expiratory volume in 1 second (FEV1) occurs alongside a decline in ability 
to undertake physical activities and social functioning, reflected in the measurement 
of clinical outcomes including dyspnea and health status.2 Regular pharmacotherapy 
using long-acting inhaled bronchodilators has been shown to provide not only rapid 
improvement in lung function, but clinically important decreases in dyspnea and exac-
erbation rate with a corresponding improvement in health status.3 Bronchodilators have 
therefore become the cornerstone of treatment for COPD of all severity stages.
Current guidelines recommend that patients with moderate to severe COPD 
  initiate therapy with long-acting bronchodilators if short-acting bronchodilators are 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
145
REvIEW
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/COPD.S19805International Journal of COPD 2012:7
not   providing sufficient symptom relief.4 Currently   available 
agents include the twice-daily long-acting β2-agonists 
(LABAs) formoterol and salmeterol and the once-daily 
anticholinergic tiotropium. Although long-acting bron-
chodilators are considered more effective and convenient 
than short-acting agents,5 symptoms remain limiting for 
many subjects.6
The shift in treatment preference from short-acting 
bronchodilators with multiple dosing per day to long-
  acting bronchodilators with once-daily or twice-daily dosing 
and prolonged duration of bronchodilation has resulted in 
improved clinical outcomes for COPD patients.7 The con-
sequent reduction in dosing frequency not only simplifies 
disease management, but has the potential to improve patient 
adherence and compliance.5
Until recently, the only available LABAs were salmeterol 
and formoterol, both of which have an approximate 12-hour 
duration of bronchodilator action, and hence are used twice 
daily for maintenance therapy in COPD. Indacaterol is the 
first once-daily long-acting β2-selective agent, sometimes 
referred to as an ultra-LABA, indicated for maintenance 
treatment in patients with moderate to severe COPD, has been 
approved in more than 40 countries (including throughout 
the European Union) at a recommended dose of 150 µg once 
daily and a maximum dose of 300 µg once daily,8 and has 
been shown to be effective and well tolerated by subjects with 
COPD during 12 weeks of treatment.9 With any new treat-
ment intended for long-term use, it is   important to   evaluate 
safety and to determine if efficacy remains unblunted with 
regular use. A thorough characterization of safety is par-
ticularly relevant for a long-acting bronchodilator, given the 
recent interest in the safety of these agents in the   treatment 
of COPD.10
The 75 µg dose of indacaterol as licensed in the US was 
evaluated only in studies of 12 weeks’ duration.11 Overall, 
the results with indacaterol 150 µg and 300 µg demonstrate 
a good profile of safety and tolerability that is comparable 
with the other evaluated long-acting bronchodilators. 
  Compared with these two doses, results with the 75 µg dose 
of indacaterol were occasionally anomalous but must be 
considered in the context that these data are less robust in 
terms of shorter length of treatment (maximum 12 weeks) and 
fewer patients exposed to this dose.12 However, in the two 
studies evaluating the 75 µg dose, the safety and tolerability 
profiles were similar to placebo.11
Few deaths occurred in any of the active treatment 
groups, and the number of deaths adjusted per patient-year 
was not increased with any of the LABA treatments relative 
to   placebo. The finding of no deaths among the indacaterol 
75 µg group should be interpreted with caution, given that 
most of the data came from two 12-week studies.12
Pharmacology, mode of action,  
and pharmacokinetics
Sequential modifications of the chemical structure of 
  catecholamines13 allowed synthesis of agonists with 
improved selectivity for the β2-adrenoreceptor and led to the 
subsequent development of short-acting β2-bronchodilators 
such as fenoterol, salbutamol (albuterol), and terbutaline, and 
the long-acting β2-agonists, salmeterol and formoterol.
In vitro studies during the preclinical development of 
indacaterol13 characterized this new agent as having high ago-
nist efficacy at the human β2-adrenoreceptor, with a binding 
affinity similar to formoterol, an intrinsic activity higher than 
salmeterol, and a functional selectivity similar to formoterol 
over the β1-adrenoreceptor, and similar to   formoterol and 
salbutamol over the β3-adrenoreceptor. In vivo, indacaterol 
produced a prolonged bronchoprotective effect against 
  pharmacologically induced bronchoconstriction, and showed 
an improved cardiovascular safety profile.14
Reports on pharmacokinetics15 showed that indacaterol 
is rapidly absorbed and distributed after inhalation, with 
a median time to reach peak serum concentrations of 
  approximately 15 minutes after single or repeated inhaled 
doses, although systemic exposure results from a composite 
of pulmonary and intestinal absorption. The faster onset 
and longer duration of action of indacaterol compared with 
some other β2-adrenoceptor agonists may be related to 
lipid membrane interactions. The sum of these small differ-
ences, including higher partitioning of indacaterol into the 
microenvironment of the receptor and its faster membrane 
permeation, is likely to contribute to its faster onset and 
longer duration of therapeutic action.16
In the toxicological assessments,17 indacaterol was 
considered negative in the standard battery of in vitro and in 
vivo genotoxicity tests, and did not raise concerns regarding 
potential carcinogenicity. There was also no evidence of 
teratogenicity in the embryo-fetal development studies. 
An analysis of the effect of age, gender, and weight on 
systemic exposure after inhalation indicated that indacaterol 
can be used safely in all age and weight groups within the 
COPD population, and regardless of gender. No difference 
was suggested either between ethnic subgroups in the 
  population analyzed.
Pharmacokinetic data taken during multiple-dose   studies 
of indacaterol 400 µg or 800 µg once daily for 14 days 
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  demonstrated rapid absorption and a mean elimination 
  half-life .30 hours, whereas in a single-dose study, doses 
between 600 µg and 2000 µg were rapidly absorbed, 
with maximum serum concentrations reached within 
15 minutes.18
Efficacy of indacaterol compared 
with established therapies
In large-scale registration studies, indacaterol provided 
24-hour bronchodilation on once-daily dosing with an effect 
that was sustained during treatment for up to 1 year.19 The 
relative effect of indacaterol on trough FEV1 (measured 
24 hours following dosing) after 12 weeks of treatment 
was reported to be 40–50 mL greater than the once-daily 
anticholinergic bronchodilator, tiotropium, and 60–100 mL 
greater than the trough FEV1 measured 12 hours after 
dosing with the twice-daily β2-agonists, salmeterol and 
formoterol20 (Figure 1).
The efficacy and safety of indacaterol was evaluated 
in an extensive Phase III clinical program in which 
patients received doses of up to 600 µg once daily for up 
to 52 weeks.20 In an analysis of data from 801 patients 
with moderate to severe COPD after 2 weeks of treatment, 
indacaterol 150 µg once daily was identified as the lowest 
dose that was numerically superior to the active comparators 
(formoterol twice daily and open-label tiotropium once daily) 
and, along with the next highest dose (300 µg), was selected 
for further evaluation.21
Chapman et al22 recently reported on the safety of 
indacaterol 150 µg and 300 µg once daily versus placebo 
during the 26-week extension phase of the 26-week open-
label tiotropium comparison study, thereby providing data 
over a total duration of 52 weeks. In their analysis, adverse 
events occurred in 76%, 77%, and 68% of subjects receiv-
ing indacaterol 150 µg, 300 µg, and placebo, respectively, 
whereas serious adverse events occurred in 10.4%, 12.3%, 
and 10.5%, respectively. There were no clinically significant 
effects with indacaterol at either dose on QTc interval or 
potassium or glucose levels.
This additional evaluation showed that indacaterol 150 µg 
and 300 µg provided statistically significant and clinically 
relevant improvements in trough FEV1 versus placebo up 
to 26 weeks.19 Although indacaterol 150 µg and 300 µg had 
similar effects on trough FEV1, the higher dose was associ-
ated with incremental benefits in terms of symptomatic relief, 
such as dyspnea, particularly for patients with more severe 
COPD. Further, the overall clinical trial program indicated 
that indacaterol has a similar safety and tolerability profile 
across all of the doses evaluated.22,23
Results of a recent 14-day crossover study24 that com-
pared indacaterol 300 µg with open-label salmeterol showed 
that indacaterol dosed once daily has a bronchodilator profile 
that is consistently numerically superior to salmeterol dosed 
twice daily. A larger 26-week comparison with blinded sal-
meterol suggested that in addition to improved bronchodilator 
efficacy, once-daily dosing with indacaterol is generally more 
effective than twice-daily salmeterol.23
COPD exacerbations were significantly reduced versus 
placebo for indacaterol 150 µg or 300 µg once daily. In 
a 52-week study,20 once-daily treatment with indacaterol 
prolonged the time to first COPD exacerbation and was 
effective in reducing the incidence and frequency of COPD 
exacerbations, with no significant difference between inda-
caterol and formoterol. Patients treated with indacaterol 
had a significantly higher percentage of days with no use of 
as-needed rescue salbutamol than placebo recipients in all 
large studies.
Only the once-daily bronchodilators (indacaterol and 
tiotropium) provided more than the 120 mL improvement 
in trough FEV1, prespecified as the threshold of clinical 
interest in several studies studies.9,19,20,23 For trough FEV1 
at week 12, indacaterol 150 µg and 300 µg were statisti-
cally superior to open-label tiotropium, indacaterol 150 µg 
was statistically superior to salmeterol, and indacaterol 
300 µg was statistically superior to formoterol. The efficacy 
of indacaterol was maintained over the study durations 
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Figure 1 Serial measurements of FEv1 from 15 minutes to 24 hours postdose 
measured  in  a  subset  with  serial  spirometry  measurements  (12-hour  serial 
spirometry subset) at week 12.
Notes: Data are least squares means 6 SE. Treatment differences: P , 0.001 for 
indacaterol (both doses) versus placebo at each time point; P , 0.05 for formoterol 
versus placebo at time points from 5 minutes to 11 hours and 45 minutes postdose; 
P , 0.05 for indacaterol 300 mg versus formoterol at 15 minutes, 2 hours, and from 
6 hours to 23 hours 45 minutes; P , 0.05 for indacaterol 600 mg versus formoterol 
at all time points apart from 5 minutes postdose.20
Abbreviations: FEv1, forced expiratory volume in 1 second; bd, twice daily; od, 
once daily.
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(ie, 6 months19,23 and 1 year20). Indacaterol has a fast onset of 
bronchodilator effect following the first dose. The mean FEV1 
measured at 5 minutes after the first dose with indacaterol 
was 110–130 mL greater than after placebo (P , 0.001), 
approximately double the corresponding values with tiotro-
pium (70 mL; P , 0.001 versus tiotropium) and salmeterol 
(60 mL; P , 0.001 versus salmeterol), and similar to formot-
erol (140 mL; not significantly different, Figure 2).
Indacaterol improved breathlessness assessed using the 
transition dyspnea index, with an effect close to or greater 
than the threshold for clinical relevance. Indacaterol had a 
similar (150 µg dose) or greater (300 µg dose) effect than 
open-label tiotropium, and a greater effect than the twice-
daily bronchodilators formoterol and salmeterol. These 
differences are evident both in terms of the effect on mean 
transition dyspnea index scores and the percentage of patients 
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Figure 2 Serial measurements of (A) FEv1 and (B) FvC from 250 minutes to 23 hours 45 minutes postdose measured in subsets with 12-hour serial spirometry at week 26.
Notes: Data are least squares means 6 SE. Treatment differences for FEv1: P = 0.05 for indacaterol (both doses) and tiotropium versus placebo at all time points; P = 0.05 
for indacaterol 300 mg versus tiotropium at 250, 215, and 5 minutes, 2 hours, 4 hours, and 23 hours 10 minutes. Treatment differences for FvC: P = 0.05 for indacaterol 
(both doses) and tiotropium versus placebo at all time points; P = 0.05 for indacaterol 300 mg versus 150 mg at 2 hours, 4 hours, 23 hours 10 minutes, and 24 hours 
45 minutes.19
Abbreviations: FvC, forced vital capacity; FEv1, forced expiratory volume in 1 second; qd, once daily.
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who achieved at least a clinically relevant improvement in 
breathlessness. Indacaterol, along with all the other broncho-
dilators, showed a statistically significant effect compared 
with placebo at later time points during the 6-month and 
1-year studies.9,19,20,23
Patients with COPD treated with indacaterol used less 
as-needed salbutamol, with a decrease of approximately 
1.5 puffs per day from baseline. The decrease was greater 
than that seen for patients receiving either tiotropium or 
formoterol. Patients receiving indacaterol also recorded 
more days when they took no salbutamol (55%–60%), 
which is more than was recorded with tiotropium (46%) 
and formoterol (52%).9,19,20,23
Exacerbation rates were numerically reduced compared 
with placebo with all the bronchodilators, but in most cases 
the effect was not statistically significant. These studies 
were not designed to measure exacerbations as a primary 
outcome, so only stable patients were recruited (annual 
exacerbation rates with placebo treatment were in the range 
0.7–1.0).9,19,20,23 Health status, assessed using the St George’s 
Respiratory Questionnaire, was improved relative to 
placebo with indacaterol and with the two twice-daily 
bronchodilators, but not with tiotropium, although it should 
be noted that tiotropium was given “open-label”. As seen in 
previous studies with bronchodilators, most treatments did 
not produce a change that exceeded the minimal clinically 
important difference when compared with placebo, but 
this was achieved with indacaterol 150 µg9,23 and with 
salmeterol.23 A similar pattern of results was seen for patients 
with severe COPD (Global Initiative for Chronic Obstructive 
Lung Disease [GOLD] stage III). This is appropriate for 
primary care, given that a recent large European study in 
primary care found that nearly 40% of patients had GOLD 
stage III or IV disease.25
Safety and tolerability compared 
with established therapies
Systemic bioavailability of β2-agonist bronchodilators can 
elicit known β2-adrenoceptor-mediated cardiovascular 
effects,26 such as palpitations, tachycardia, changes in 
blood pressure, and electrocardiographic abnormalities 
such as a prolonged QT interval, as well as hypokalemia, 
hyperglycemia, headache, and skeletal muscle tremor. The 
available data for indacaterol overall support an excellent 
safety profile, with no relevance of its long duration of action 
in terms of side effects.
The bronchodilator efficacy of indacaterol increased from 
the first dose to the measurements performed at the end of 
12 weeks of treatment. In a longer-term study, the efficacy of 
indacaterol 150 µg once daily was not reduced with repeated 
dosing for 6 or 12 months, showing persistence of broncho-
dilator response without tachyphylaxis.22
In COPD patients, a large data set was generated from 
various studies primarily aimed at dose ranging and safety 
analysis.9,27 Safety variables were also secondary endpoints 
in all studies primarily aimed at efficacy endpoints. Overall, 
the rate of adverse events was low and similar across treat-
ment groups in the different trials. There was no evidence 
of drug-related or dose-related changes in hematological 
parameters, and no clinically relevant differences were 
observed between treatment groups in any of the biochemi-
cal variables measured.
The incidence of other β2-agonist-related effects, includ-
ing muscle spasm, headache, and tremor, was comparable 
between indacaterol and placebo groups. Data generated 
across a wide dose range support a good cardiovascular 
safety, with no clinically significant differences in mean 
pulse rate, no drug-related trends in systolic or diastolic 
blood pressure, no statistically significant differences in mean 
QTc interval, and no differences in the numbers of subjects 
with notable QTc interval increases. Serious adverse events 
in subjects receiving indacaterol occurred with frequencies 
similar or inferior to placebo groups, and none were clas-
sified as suspected to be related to the study drug in COPD 
patients in the trials reported.
In various trials, cough upon drug inhalation was reported 
with a mean frequency ranging from 2.9% to 17.8% in 
indacaterol groups and 0.9% to 7.3% in placebo groups. 
The cough was described as occurring within 15 seconds 
  following drug inhalation, with a median duration of 
6   seconds, and having no association with bronchospasm or 
increased study discontinuation rates.9
More than 4000 patients have completed treatment 
with indacaterol so far in controlled clinical studies of at 
least 12 weeks’ duration, and no significant safety concerns 
have arisen. Safety has been evaluated during up to 1 year’s 
treatment with the approved daily doses of 150 µg and 300 µg, 
and with a higher (unlicensed) dose of 600 µg once daily. 
Adverse events generally occurred with a similar incidence in 
the indacaterol and placebo groups. The most common adverse 
events reflected the symptoms and manifestations of COPD, 
such as worsening of COPD and respiratory tract infections. 
As with the other long-acting bronchodilators,28 indacaterol 
has a good profile of cardiovascular safety in patients with 
COPD, and has little or no effect on vital signs and QTc 
interval, the derived electrocardiographic measurement 
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used to indicate risk of arrhythmias.29 Approximately 20% 
of patients experience a mild transient cough in the first few 
minutes after inhalation of indacaterol. This typically lasts for 
several seconds and is not associated with loss of efficacy, 
increased dropout rates, or any safety concerns.
Patient considerations
Indacaterol may offer small but clinically important advan-
tages in the treatment of COPD. The dosing regimen requir-
ing less frequent dosing was shown to be associated with 
improved patient compliance with therapy.30 Therefore, an 
effective once-daily β2-agonist bronchodilator would add 
a significant advance to the therapeutic toolbox for COPD. 
Long-term safety of a new treatment is important for subjects 
with COPD, who are often elderly, frequently have significant 
comorbidity, and tend to be receiving multiple medications.31 
In all studies designed to investigate whether indacaterol has 
the same tolerability as that of the LABAs already on the 
market, indacaterol was well tolerated at all doses and with 
a good overall safety profile.32
The inhalation device used for indacaterol, ie, the 
Breezhaler, is a simple dry powder inhaler in which capsules 
of powdered medication are loaded, pierced, and inhaled. 
While similar in function to the Handihaler used for tiotro-
pium, the Breezhaler is a lower resistance device. When 
compared with the Handihaler in a 2-week patient handling 
and preference study, patients handled both devices well 
and without error, but preferred the smaller size and lower 
resistance characteristics of the Breezhaler.33
Conclusion, place in therapy
Indacaterol is a new once-daily LABA with a rapid onset 
of action (within 5 minutes), a peak effect at approximately 
3 hours, and a duration of bronchodilation lasting at least 
24 hours. Indacaterol has become the first effective once-
daily LABA that is widely approved for use in COPD. 
Indacaterol, now approved in the European Union and US 
for COPD, provides effective 24-hour bronchodilation and 
a fast onset of action, with an efficacy at least comparable 
or superior to current bronchodilator therapy standards. 
We restrict our discussion only to the European product 
because in the US there were only two studies that evaluated 
12 weeks’ duration. The data from clinical development 
support a favorable safety and tolerability profile within 
the β2-agonist drug class, with no relevant safety issues 
identified. The recommended dose is 150 µg once daily, 
delivered using a single-dose dry powder inhaler device. 
A 300 µg per capsule presentation for once-daily dosing is 
also approved and may provide additional clinical benefit 
for patients with severe COPD. The maximum dose is 
300 µg once daily. As expected, improvements in lung 
function have translated into correspondingly beneficial 
effects on patient-reported outcomes, including significant 
reductions in exacerbations, dyspnea, and days with poor 
control, and clinically meaningful improvements in health-
related quality of life, particularly when comparisons are 
made with placebo.
Some evidence shows that indacaterol is suitable for use 
as first-line monotherapy in COPD patients with moderate 
disease (GOLD stage II) and beyond that do not require 
inhaled corticosteroids as per GOLD guidelines, or in com-
bination with an inhaled corticosteroid in severe or very 
severe patients with repeated exacerbations. As with long-
acting bronchodilators, a short-acting bronchodilator such as 
salbutamol can be employed as on-demand rescue medication 
if needed. Further research should provide evidence on the 
benefits and safety profile of combining indacaterol with a 
long-acting anticholinergic bronchodilator.
Current COPD guidelines recommend inhaled bron-
chodilators as the mainstay of COPD pharmacotherapy 
and at least one long-acting inhaled bronchodilator as 
first-line maintenance therapy for patients with moderate 
symptomatic COPD, without signifying a preference for 
either a LABA or a once-daily long-acting antimuscarinic 
(LAMA). However, in actual practice, when a single long-
acting inhaled bronchodilator is prescribed, it is most often 
a LAMA (tiotropium), rather than a twice-daily LABA 
(salmeterol or formoterol). The reason for this real world 
preference is unclear, but may be related to the greater 
convenience of the once-daily LAMA than the twice-daily 
LABA, a distinction that will be eliminated when indacaterol 
becomes widely available.
The GOLD guidelines also recommend combining a 
LAMA and a LABA in COPD patients not responding sat-
isfactorily to monotherapy with either class of long-acting 
inhaled bronchodilator, a strategy that has been found to 
result in additive improvements in lung function in short-term 
clinical trials. However, this recommendation is infrequently 
followed; instead, in patients not responding to tiotropium 
alone, a LABA-inhaled corticosteroid combination is gener-
ally added as the next step. The availability of a once-daily 
LABA, such as indacaterol, would provide a convenient 
alternative to adding a twice-daily LABA-inhaled corticos-
teroid to a once-daily LAMA because the combined use of 
tiotropium and indacaterol in separate devices would entail 
only once-daily dosing.
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Indacaterol provides a level of bronchodilation that 
is similar to tiotropium and greater than the twice-daily 
agents, formoterol and salmeterol. The measures of breath-
lessness and health status used in the indacaterol studies 
encompass components reflecting symptoms and the abil-
ity to undertake activities of daily living. Indacaterol was 
effective at reducing breathlessness, the most troublesome 
COPD symptom, and the 300 µg dose was significantly 
more effective in this regard than tiotropium and the twice-
daily agents.
The beneficial effects of indacaterol on breathless-
ness and health status in GOLD stage II patients suggest 
that the overall study results provide a useful guide to the 
level of efficacy that may be expected in milder patients 
who may be seen predominantly in a primary care patient 
population. Indacaterol can also be combined with a 
once-daily inhaled corticosteroid, thus providing a more 
convenient once-daily alternative to existing twice-daily 
LABA-inhaled corticosteroid combinations (fluticasone-
salmeterol and budesonide-formoterol) for the treatment 
of severe COPD.
A noticeable side effect has been cough, which has 
been mild and with attenuation over time and without pre-
mature withdrawal from the trials. It has occurred within 
seconds of inhalation with rapid resolution, and has not 
been associated with bronchospasm. The mechanism of the 
cough remains unclear but presumably is related to a drug-
specific stimulant effect on cough receptors in the upper/
central airways; it seems that tachyphylaxis to this effect 
develops over time. No clinically meaningful effects have 
been noted on cardiovascular parameters, including heart 
rate, blood pressure, or QTc interval, or on serum potassium 
or blood glucose.
A patient with confirmed COPD who remains troubled 
by symptoms limiting daily activities despite a short-acting 
bronchodilator is a candidate for long-acting bronchodilator 
treatment. Factors to consider are the patient’s symptomatic 
response and preference, as well as drug side effects and 
cost. Indacaterol is attractive as a once-daily bronchodilator 
because it has slightly greater efficacy than the twice-daily 
bronchodilators. On the basis of the evidence reviewed, we 
conclude that once-daily indacaterol is an effective and ben-
eficial maintenance bronchodilator treatment for patients with 
moderate to severe COPD, including patients with GOLD 
stage II disease.
Bronchodilators are central in the symptomatic manage-
ment of COPD. It is likely that once-daily dosing of a bron-
chodilator would be a significant convenience and probably 
a compliance-enhancing advantage, leading to improved 
overall clinical outcomes in patients with COPD.
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